TNFR2: The new Treg switch?

Oncoimmunology. 2017 Sep 21;7(1):e1373236. doi: 10.1080/2162402X.2017.1373236. eCollection 2017.

Abstract

Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting.

Keywords: Immune checkpoint; Immunomodulation; Immunotherapy; TNFR2; Treg.

Publication types

  • Research Support, Non-U.S. Gov't